EDITAS MEDICINE, INC. Research and Development Expense
EDITAS MEDICINE, INC. (EDIT) reported Research and Development Expense of $20.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- EDITAS MEDICINE, INC. research and development expense for the quarter ending 2026-06-30 was $20.18M, a 24.71% increase year-over-year.
- EDITAS MEDICINE, INC. research and development expense for the quarter ending 2026-03-31 was $17.60M, a 33.82% decline year-over-year.
- EDITAS MEDICINE, INC. research and development expense for the quarter ending 2025-12-31 was $27.40M, a 43.63% decline year-over-year.
- EDITAS MEDICINE, INC. research and development expense for the quarter ending 2025-09-30 was $19.77M, a 58.49% decline year-over-year.
- EDITAS MEDICINE, INC. research and development expense for fiscal 2025 was $89.95M, a 54.85% decline from fiscal 2024.
- EDITAS MEDICINE, INC. research and development expense for fiscal 2024 was $199.25M, a 12.16% increase from fiscal 2023.
- EDITAS MEDICINE, INC. research and development expense for fiscal 2023 was $177.65M, a 1.54% increase from fiscal 2022.
- EDITAS MEDICINE, INC. research and development expense for fiscal 2022 was $174.96M, a 22.77% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.18M 10-Q · filed 2026-08-05 | $37.78M 10-Q · filed 2026-08-05 | $65.18M derived: sum of 3 quarters · filed 2026-08-05 | $84.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $17.60M 10-Q · filed 2026-05-05 | $45.00M derived: sum of 2 quarters · filed 2026-05-05 | $64.78M derived: sum of 3 quarters · filed 2026-05-05 | $80.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $27.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $47.18M derived: sum of 2 quarters · filed 2026-03-09 | $63.36M derived: sum of 3 quarters · filed 2026-08-05 | $89.95M 10-K · filed 2026-03-09 |
| 2025-09-30 | $19.77M 10-Q · filed 2025-11-10 | $35.96M derived: sum of 2 quarters · filed 2026-08-05 | $62.55M 10-Q · filed 2025-11-10 | $111.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $16.18M 10-Q · filed 2026-08-05 | $42.77M 10-Q · filed 2026-08-05 | $91.39M derived: sum of 3 quarters · filed 2026-08-05 | $139.02M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $26.59M 10-Q · filed 2026-05-05 | $75.20M derived: sum of 2 quarters · filed 2026-05-05 | $122.84M derived: sum of 3 quarters · filed 2026-05-05 | $177.05M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $48.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $96.25M derived: sum of 2 quarters · filed 2026-03-09 | $150.46M derived: sum of 3 quarters · filed 2026-03-09 | $199.25M 10-K · filed 2026-03-09 |
| 2024-09-30 | $47.64M 10-Q · filed 2025-11-10 | $101.85M derived: sum of 2 quarters · filed 2025-11-10 | $150.64M 10-Q · filed 2025-11-10 | $220.19M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $54.21M 10-Q · filed 2025-08-12 | $103.00M 10-Q · filed 2025-08-12 | $172.55M derived: sum of 3 quarters · filed 2025-08-12 | $213.06M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $48.79M 10-Q · filed 2025-05-12 | $118.34M derived: sum of 2 quarters · filed 2025-05-12 | $158.85M derived: sum of 3 quarters · filed 2025-05-12 | $188.63M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $69.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $110.07M derived: sum of 2 quarters · filed 2025-03-05 | $139.85M derived: sum of 3 quarters · filed 2025-03-05 | $177.65M 10-K · filed 2025-03-05 |
| 2023-09-30 | $40.51M 10-Q · filed 2024-11-04 | $70.29M derived: sum of 2 quarters · filed 2024-11-04 | $108.09M 10-Q · filed 2024-11-04 | $160.09M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $29.78M 10-Q · filed 2024-08-07 | $67.58M 10-Q · filed 2024-08-07 | $119.58M derived: sum of 3 quarters · filed 2025-03-05 | $160.91M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $37.80M 10-Q · filed 2024-05-08 | $89.80M derived: sum of 2 quarters · filed 2025-03-05 | $131.13M derived: sum of 3 quarters · filed 2025-03-05 | $174.79M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $93.32M derived: sum of 2 quarters · filed 2025-03-05 | $136.98M derived: sum of 3 quarters · filed 2025-03-05 | $174.96M 10-K · filed 2025-03-05 |
| 2022-09-30 | $41.33M 10-Q · filed 2023-11-03 | $84.98M derived: sum of 2 quarters · filed 2023-11-03 | $122.96M 10-Q · filed 2023-11-03 | $160.51M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $43.66M 10-Q · filed 2023-08-02 | $81.64M 10-Q · filed 2023-08-02 | $119.19M derived: sum of 3 quarters · filed 2024-02-28 | $148.45M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $37.98M 10-Q · filed 2023-05-05 | $75.53M derived: sum of 2 quarters · filed 2024-02-28 | $104.79M derived: sum of 3 quarters · filed 2024-02-28 | $138.55M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $37.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $66.82M derived: sum of 2 quarters · filed 2024-02-28 | $100.57M derived: sum of 3 quarters · filed 2024-02-28 | $142.51M 10-K · filed 2024-02-28 |
| 2021-09-30 | $29.27M 10-Q · filed 2022-11-02 | $63.02M derived: sum of 2 quarters · filed 2022-11-02 | $104.95M 10-Q · filed 2022-11-02 | $166.46M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $33.75M 10-Q · filed 2022-08-03 | $75.69M 10-Q · filed 2022-08-03 | $137.19M derived: sum of 3 quarters · filed 2023-02-22 | $171.11M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $41.94M 10-Q · filed 2022-05-04 | $103.44M derived: sum of 2 quarters · filed 2023-02-22 | $137.36M derived: sum of 3 quarters · filed 2023-02-22 | $165.36M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $61.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $95.42M derived: sum of 2 quarters · filed 2023-02-22 | $123.43M derived: sum of 3 quarters · filed 2023-02-22 | $158.00M 10-K · filed 2023-02-22 |
| 2020-09-30 | $33.92M 10-Q · filed 2021-11-09 | $61.92M derived: sum of 2 quarters · filed 2021-11-09 | $96.49M 10-Q · filed 2021-11-09 | $131.28M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $28.01M 10-Q · filed 2021-08-05 | $62.58M 10-Q · filed 2021-08-05 | $97.37M derived: sum of 3 quarters · filed 2022-02-24 | $120.07M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $34.57M 10-Q · filed 2021-05-06 | $69.36M derived: sum of 2 quarters · filed 2022-02-24 | $92.06M derived: sum of 3 quarters · filed 2022-02-24 | $115.63M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $34.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $57.49M derived: sum of 2 quarters · filed 2022-02-24 | $81.06M derived: sum of 3 quarters · filed 2022-02-24 | $96.90M 10-K · filed 2022-02-24 |
| 2019-09-30 | $22.70M 10-Q · filed 2020-11-06 | $46.27M derived: sum of 2 quarters · filed 2020-11-06 | $62.11M 10-Q · filed 2020-11-06 | $81.30M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $23.57M 10-Q · filed 2020-08-07 | $39.41M 10-Q · filed 2020-08-07 | $58.60M derived: sum of 3 quarters · filed 2021-02-26 | $76.04M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $15.84M 10-Q · filed 2020-05-08 | $35.04M derived: sum of 2 quarters · filed 2021-02-26 | $52.48M derived: sum of 3 quarters · filed 2021-02-26 | $85.20M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $19.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $36.64M derived: sum of 2 quarters · filed 2021-02-26 | $69.36M derived: sum of 3 quarters · filed 2021-02-26 | $90.65M 10-K · filed 2021-02-26 |
| 2018-09-30 | $17.44M 10-Q · filed 2019-11-12 | $50.16M derived: sum of 2 quarters · filed 2019-11-12 | $71.46M 10-Q · filed 2019-11-12 | $97.89M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $32.72M 10-Q · filed 2019-08-07 | $54.02M 10-Q · filed 2019-08-07 | $80.44M derived: sum of 3 quarters · filed 2020-02-26 | $100.84M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $21.30M 10-Q · filed 2019-05-08 | $47.72M derived: sum of 2 quarters · filed 2020-02-26 | $68.12M derived: sum of 3 quarters · filed 2020-02-26 | $85.44M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $26.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $46.82M derived: sum of 2 quarters · filed 2020-02-26 | $64.14M derived: sum of 3 quarters · filed 2020-02-26 | $83.16M 10-K · filed 2020-02-26 |
| 2017-09-30 | $20.40M 10-Q · filed 2018-11-08 | $37.71M derived: sum of 2 quarters · filed 2018-11-08 | $56.73M 10-Q · filed 2018-11-08 | $83.57M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $17.32M 10-Q · filed 2018-08-07 | $36.34M 10-Q · filed 2018-08-07 | $63.17M derived: sum of 3 quarters · filed 2019-03-01 | $74.01M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $19.02M 10-Q · filed 2018-05-04 | $45.86M derived: sum of 2 quarters · filed 2019-03-01 | $56.69M derived: sum of 3 quarters · filed 2019-03-01 | $67.12M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $26.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $37.67M derived: sum of 2 quarters · filed 2019-03-01 | $48.10M derived: sum of 3 quarters · filed 2019-03-01 | $56.98M 10-K · filed 2019-03-01 |
| 2016-09-30 | $10.83M 10-Q · filed 2017-11-08 | $21.26M derived: sum of 2 quarters · filed 2017-11-08 | $30.14M 10-Q · filed 2017-11-08 | $35.97M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $10.43M 10-Q · filed 2017-08-09 | $19.31M 10-Q · filed 2017-08-09 | $25.14M derived: sum of 3 quarters · filed 2018-03-08 | $28.99M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $8.88M 10-Q · filed 2017-05-15 | $14.71M derived: sum of 2 quarters · filed 2018-03-08 | $18.56M derived: sum of 3 quarters · filed 2018-03-08 | $25.84M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $9.68M derived: sum of 2 quarters · filed 2018-03-08 | $16.96M derived: sum of 3 quarters · filed 2018-03-08 | $18.85M 10-K · filed 2018-03-08 |
| 2015-09-30 | $3.85M 10-Q · filed 2016-11-09 | $11.13M derived: sum of 2 quarters · filed 2016-11-09 | $13.02M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $7.28M 10-Q · filed 2016-08-10 | $9.17M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $1.89M 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | $5.07M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |